FWY003

Unknown / undisclosed

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Geographic Atrophy
NCT07441642 · Novartis Pharmaceuticals
2026-03-09 – 2029-08-22 · Geographic Atrophy Secondary to Age-related Macular Degeneration
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, 2 of them ahead of this one.

This drug's own stage for Geographic Atrophy: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
FWY003: this drugPhase 2UndisclosedComplement Factor Bnot yet gradedNo reviewed efficacy summary in this indication
Iptacopan (Fabhalta)
Approved(overall)
Small moleculeComplement Factor B
Partial signal(overall)
No reviewed efficacy summary in this indication
HRS-5965
Phase 3(overall)
UndisclosedComplement Factor B
not yet graded(overall)
No reviewed efficacy summary in this indication
VonaprumentPhase 3Antibody fragmentComplement C1qPartial signalNo reviewed efficacy summary in this indication
OpRegenPhase 2Cell therapy—not yet gradedNo reviewed efficacy summary in this indication
ALN-CFB
Phase 1/2(overall)
RNA / oligonucleotideComplement Factor B
not yet graded(overall)
No reviewed efficacy summary in this indication
ASP7317Phase 1Cell therapy—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow FWY003 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
August 2029 (1)
Phase 2Geographic AtrophyRecruiting
Est. primary completion 2029-08-21 · NCT07441642 · CT.gov ↗
What to watch

See the full readout calendar ↗